MiNK Therapeutics, Inc. financial data

Symbol
INKT on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
149 Fifth Avenue, Suite 500, New York, NY
State of incorporation
DE
Fiscal year end
December 31
Former names
AgenTus Therapeutics, Inc. (to 3/18/2021), AgenTus Therapeutics, Inc. (to 3/18/2021)
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 64 % -45.1%
Return On Equity 76.1 % -78.5%
Return On Assets -189 % -10%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 39.5M shares +14.6%
Common Stock, Shares, Outstanding 34.6M shares +2.19%
Entity Public Float 20.5M USD +211%
Common Stock, Value, Issued 395 USD +14.5%
Weighted Average Number of Shares Outstanding, Basic 39.5M shares +14.6%
Weighted Average Number of Shares Outstanding, Diluted 39.5M shares +14.6%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 8.24M USD -54.2%
General and Administrative Expense 5.69M USD -22.2%
Operating Income (Loss) -14.3M USD +43.6%
Net Income (Loss) Attributable to Parent -13.8M USD +44.4%
Earnings Per Share, Basic -0.38 USD/shares +47.9%
Earnings Per Share, Diluted -0.38 USD/shares +47.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 6.33M USD -1.1%
Other Assets, Current 11.2K USD -61.8%
Assets, Current 6.58M USD +1.62%
Property, Plant and Equipment, Net 800K USD -19.4%
Assets 7.37M USD -1.16%
Accounts Payable, Current 2.36M USD -44.8%
Accrued Liabilities, Current 2.65M USD -31.2%
Liabilities, Current 7.4M USD -28.8%
Other Liabilities, Noncurrent 2.94K USD -95.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax -673K USD -115%
Retained Earnings (Accumulated Deficit) -142M USD -10.8%
Stockholders' Equity Attributable to Parent -17.6M USD -29.3%
Liabilities and Equity 7.37M USD -1.16%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.54M USD +41.8%
Net Cash Provided by (Used in) Financing Activities 5.01M USD
Net Cash Provided by (Used in) Investing Activities -13.5K USD
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 39.5M shares +14.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 2.45M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6.33M USD -1.1%
Interest Paid, Excluding Capitalized Interest, Operating Activities 5.12K USD -48.6%
Deferred Tax Assets, Valuation Allowance 29.7M USD +31%
Deferred Tax Assets, Gross 29.7M USD +31%
Depreciation 53.8K USD +17.8%
Payments to Acquire Property, Plant, and Equipment 13.5K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -14.1M USD +43.4%
Property, Plant and Equipment, Gross 1.45M USD +7.33%
Preferred Stock, Shares Authorized 5M shares
Share-based Payment Arrangement, Expense 3.52M USD +2.89%
Interest Expense 848K USD +14%